FDA Safety Database Reveals 19 Neurological Side Effects Linked to GLP-1 Weight Loss Drugs
An analysis of nearly 29,000 adverse event reports found 19 distinct neurological side effects associated with GLP-1 drugs, with nearly half occurring within the first month of treatment.
Quick Facts
What This Study Found
Across six GLP-1 receptor agonists (exenatide, liraglutide, lixisenatide, dulaglutide, semaglutide, and tirzepatide), 19 distinct neurological adverse event signals were identified from 28,953 reports in the FAERS database spanning 2005–2024.
The most notable signals included dizziness, tremor, dysgeusia (taste distortion), lethargy, taste disorder, presyncope (near-fainting), parosmia (smell distortion), allodynia (pain from normally non-painful touch), and hypoglycemic unconsciousness.
Time-to-onset analysis showed a median latency of 32 days (IQR 7–122 days), with 45.28% of neurological events occurring within the first 30 days of treatment initiation. These signals were confirmed across multiple statistical methods including reporting odds ratios, proportional reporting ratios, information components, and empirical Bayes geometric means.
Key Numbers
How They Did This
The researchers analyzed the FDA Adverse Event Reporting System (FAERS) database from Q2 2005 through Q3 2024. They used a statistical approach called disproportionality analysis, which compares how often a side effect is reported with a specific drug versus all other drugs. They applied four different statistical methods to confirm their findings, and also analyzed how quickly after starting the drug each neurological event appeared.
Why This Research Matters
With tens of millions of people now taking GLP-1 drugs for weight loss and diabetes, understanding their neurological safety profile is critical. This is the largest pharmacovigilance study to systematically catalog neurological side effects across all six approved GLP-1 receptor agonists, giving doctors a clearer picture of what to watch for — especially in the crucial first month of treatment.
The Bigger Picture
As GLP-1 drugs become some of the most prescribed medications worldwide, post-market safety surveillance becomes increasingly important. Most clinical trials focus on metabolic and gastrointestinal effects, so neurological side effects may be underrecognized. This study adds to a growing body of pharmacovigilance research suggesting that GLP-1 receptor agonists have effects on the nervous system that warrant closer study in prospective clinical trials.
What This Study Doesn't Tell Us
The FAERS database relies on voluntary reporting, which means side effects may be underreported or overreported. The data can't prove that GLP-1 drugs actually caused these neurological events — only that they were reported together. Confounding factors like other medications, underlying conditions, and the demographics of who reports aren't fully controlled for. The analysis also can't determine how common these events actually are in the overall population taking these drugs.
Questions This Raises
- ?Do specific GLP-1 drugs carry higher risk for particular neurological side effects than others?
- ?What biological mechanisms might explain how GLP-1 receptor activation in the brain leads to neurological adverse events?
- ?Would prospective clinical trials designed to monitor neurological outcomes confirm these pharmacovigilance signals?
Trust & Context
- Key Stat:
- 45.28% of neurological adverse events occurred within the first 30 days of starting a GLP-1 drug
- Evidence Grade:
- This is a pharmacovigilance database study using voluntary adverse event reports, which can identify safety signals but cannot establish causation. It sits below randomized controlled trials and prospective cohort studies in the evidence hierarchy.
- Study Age:
- Published in 2025, this study uses the most recent FAERS data available through Q3 2024, making it highly current and relevant to the ongoing GLP-1 safety discussion.
- Original Title:
- Pharmacovigilance analysis of neurological adverse events associated with GLP-1 receptor agonists based on the FDA Adverse Event Reporting System.
- Published In:
- Scientific reports, 15(1), 18063 (2025)
- Authors:
- Chen, He, Liu, Sixing, Gao, Shuai, Shi, Hangyu, Yan, Yan, Xu, Yixing, Fang, Jiufei, Wang, Weiming, Chen, Huan, Liu, Zhishun
- Database ID:
- RPEP-10382
Evidence Hierarchy
Frequently Asked Questions
What neurological side effects were found with GLP-1 drugs?
The study identified 19 neurological signals including dizziness, tremor, taste changes (dysgeusia), lethargy, near-fainting (presyncope), smell distortion (parosmia), pain sensitivity (allodynia), and loss of consciousness from low blood sugar. These were found across all six GLP-1 drugs studied.
How soon after starting a GLP-1 drug do neurological side effects typically appear?
The median time to onset was 32 days, and 45.28% of neurological events occurred within the first 30 days of treatment. This suggests the early weeks of GLP-1 therapy may be a critical window for monitoring neurological symptoms.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-10382APA
Chen, He; Liu, Sixing; Gao, Shuai; Shi, Hangyu; Yan, Yan; Xu, Yixing; Fang, Jiufei; Wang, Weiming; Chen, Huan; Liu, Zhishun. (2025). Pharmacovigilance analysis of neurological adverse events associated with GLP-1 receptor agonists based on the FDA Adverse Event Reporting System.. Scientific reports, 15(1), 18063. https://doi.org/10.1038/s41598-025-01206-9
MLA
Chen, He, et al. "Pharmacovigilance analysis of neurological adverse events associated with GLP-1 receptor agonists based on the FDA Adverse Event Reporting System.." Scientific reports, 2025. https://doi.org/10.1038/s41598-025-01206-9
RethinkPeptides
RethinkPeptides Research Database. "Pharmacovigilance analysis of neurological adverse events as..." RPEP-10382. Retrieved from https://rethinkpeptides.com/research/chen-2025-pharmacovigilance-analysis-of-neurological
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.